Moneycontrol
HomeNewsTrendsHealthInterview I Our model may aid government's targeted healthcare interventions, improve outcomes: Ashoka University 

Interview I Our model may aid government's targeted healthcare interventions, improve outcomes: Ashoka University 

Ashoka University scientists say the ability of the disease modelling system they have developed with Thoughtworks to predict disease progression, prevalence and, in the case of pandemics, the likely caseload and so forth, has far-reaching implications for healthcare interventions in the country.

May 26, 2022 / 09:33 IST
Story continues below Advertisement

Gautam Menon, one of the leading voices in India assessing the COVID-19 pandemic's trajectory, is a professor of physics and biology at Ashoka University and an adjunct professor at the Tata Institute of Fundamental Research, Mumbai. Prior to joining Ashoka, he was associated with the Institute of Mathematical Sciences, Chennai.

Debayan Gupta is an assistant professor of computer science at Ashoka University and a visiting professor and research affiliate at the Massachusetts Institute of Technology in the USA. Prior to his assignment at Ashoka, he was a full-time faculty member at MIT.

Story continues below Advertisement

In this interview, Menon and Gupta talk about BharatSim, India’s first ultra-large scale simulation of 100 million to 1 billion agents representing the population of India, developed in collaboration with technology company Thoughtworks, that has the potential to enable Indian researchers to formulate strategies for management of transmissible and non-transmissible diseases. Edited excerpts:

How is this disease modelling system different from other systems and how does it work?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show